Congenital Cytomegalovirus: a "Now" Problem-No Really, Now

Despite the clear need, progress toward a vaccine for congenital cytomegalovirus (CMV) has been slow. However, recent events have provided new interest, and several vaccine candidates are either in clinical trials or the trials are close to starting. In this issue of Clinical and Vaccine Immunology,...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and vaccine immunology 2017-01, Vol.24 (1)
Main Author: Bernstein, David I
Format: Article
Language:English
Subjects:
Animals
Antibodies, Viral
Arenaviridae
Cytomegalovirus - immunology
Cytomegalovirus Infections - congenital
Cytomegalovirus Vaccines - immunology
Guinea Pigs
Herpesviridae
Humans
Vaccines, Combined
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite the clear need, progress toward a vaccine for congenital cytomegalovirus (CMV) has been slow. However, recent events have provided new interest, and several vaccine candidates are either in clinical trials or the trials are close to starting. In this issue of Clinical and Vaccine Immunology, Schleiss and colleagues show that a nonreplicating lymphocytic choriomeningitis virus (rLCMV)-vectored vaccine expressing CMV glycoprotein B (gB) and/or pp65 induces B and T cells and improves pup survival in a guinea pig model of congenital CMV infection (Clin Vaccine Immunol 24:e00300-16, 2017, https://doi.org/10.1128/CVI.00300-16). The combination vaccine appeared to be the most effective.
ISSN:1556-6811
1556-679X
DOI:10.1128/CVI.00491-16